John Libbey Eurotext

Bulletin du Cancer

Bulletin du Cancer

Volume 96, special issue 4, décembre 2009

MENU

Volume 96, special issue 4, décembre 2009

Éditorial

Article Les mutations Kras et le traitement ciblé dans les carcinomes bronchiques non à petites cellules et les cancers colorectaux (p.3-4)
C Massard, T André

Synthèse

Article Mouse models of K-ras-initiated oncogenesis (p.5-14)
C Barrière, F El Marjou, D Louvard, S Robine

Article Technical considerations for KRAS testing in colorectal cancer. The pathologist’s point of view (p.15-22)
F Bibeau, H Frugier, A Denouel, J-C Sabourin, F Boissiere-Michot

Article Pronostic role of KRAS mutation in colorectal cancer (p.23-30)
F Di Fiore, P Michel

Article Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients (p.31-40)
D Smith, C Bosacki, Y Merrouche

Article Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis (p.41-6)
E Assenat, M Ychou

Article Technical considerations for KRAS testing in colorectal cancer. The biologist’s point of view (p.47-56)
H Blons, P Laurent-Puig

Article Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value (p.57-68)
D Planchard, Y Loriot, B Besse

Article Targeting KRAS pathway in NSCLC therapy (p.69-74)
S Le Moulec, Y Loriot, J-C Soria

Article KRAS status versus EGFR status in lung cancer therapy (p.75-83)
L Lacroix, B Besse, J-M Bidart, J Bosq

Article Cutaneous side effects of EGF receptor inhibitors (p.85-91)
D Nassar, B Soutou, S Aractingi